Background The use of one’s own cells to treat tumors is typified by chimeric antigen receptor T cells (CAR T) therapy yet cells with anti-tumor properties being investigated continues to grow. We have previously proposed a new strategy using tumor-targeted mast cells (MC) obtained from autologous sources and demonstrated proof-of concept previously in vitro and in vivo.1–4
Methods A human HER2/neu-specific IgE was used to arm human adipose-derived MC (ADMC) through the high affinity IgE receptor (FceRI) and intravenously (i.v.) injected into HER2/neu human tumor-cell bearing immunocompromised mice.
Results It is shown for the first time that HER2/neu IgE-sensitized MC injected i.v. target and inhibit HER2/neu-positive tumors.
Conclusions These studies provide further proof of concept that MC have anti-tumor properties and could possibly provide another strategy for developing adoptive cell transfer therapeutics for patients.
Acknowledgements CLK was funded by NIH/NCI grant numbers 1R15CA246430 and 1R15CA283490, Specialized Center of Research grant and Pilot grant from UNC-Chapel Hill, Lineberger Cancer Center
Plotkin J, Kepley, CL. Human mast cells from adipose tissue target and induce apoptosis of breast cancer cells. Front. Immunol. February 8, 2019.
Fereydouni M, Kepley CL. Human tumor targeted cytotoxic mast cells for cancer immunotherapy. Front. Oncol. 2022 Apr 22;12:871390.
Elnaz Ahzini, Mohammad Fereydouni, Kepley CL. Identification and characterization of tunneling nanotubes involved in human mast cell FceRI-mediated apoptosis of cancer cells, Cancers 2022 Jun 14;14(12):2944.
Fereydouni M, Motaghed M, Ahani E, Kafri T, Dellinger K, Metcalfe DD and Kepley CL. Harnessing the anti-tumor mediators in mast cells as a new strategy for adoptive cell transfer for cancer. Front. Oncol. 2022;12:830199.
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.